An interventional study of Circadian/Sleep (C/S) in Overweight Adolescents, Sleep and Insulin Sensitivity, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 14 Years to 19 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Insulin Resistance by University of Colorado, Denver — 5 open to participants now, 7 under way, none of them phase 3. Insulin Resistance · University of Colorado, Denver.
Among the 24 studies in Insulin Resistance by University of Colorado, Denver, this one is the 7th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 with no phase, and was the 24th registered.
2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.
Browse Insulin Resistance studies →5 of the 24 studies in Insulin Resistance by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 18–89
University of Colorado, Denver · Sites in United States
Ages 18–70 · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 13–16
University of Colorado, Denver · Sites in United States
Ages 9–14 · Men only
By country, each count listing its studies:
Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.
This study: 14 Years to 19 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 3
First in 2004; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 40 across 2,371 interventional studies indexed under Insulin Resistance.
Median enrollment 60 across the 15 interventional studies, 42 across the 8 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
1 of the studies in Insulin Resistance by University of Colorado, Denver that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011147University of Colorado, DenverPrimary Care Pragmatic, Real World Experience for Automated Insulin Delivery | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Insulin Resistance by University of Colorado, Denver, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Many teenagers get too little and late timed sleep. High body weight and diabetes are increasing in teenagers as well. This study plans to learn more about whether improving sleep habits can help improve how the body regulates blood sugar and energy use in teenagers who have higher body weight. To answer this question, the investigators plan to enroll teenagers who get \<7 hours of sleep on school nights and measure changes in blood sugars and energy use after two weeks of typical sleep (sleeping on their normal school schedule) and two weeks of a sleep intervention that includes spending longer time in bed at night, melatonin, and morning light.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Habitual sleep schedule
1h additional time in bed, melatonin 2h before bedtime, and 30 minutes bright light after waking
Behavioral: Circadian/Sleep (C/S)
1h additional time in bed, melatonin 2h before bedtime, and 30 minutes bright light after waking
Insulin sensitivity
Matsuda Index will be calculated from a mixed meal tolerance test (MMTT); higher values indicate better insulin sensitivity.
Time frame: Assessed at 2 weeks following each condition
Total daily energy expenditure (TDEE)
Assessed with doubly labeled water. Higher values indicate greater energy expenditure
Time frame: Assessed for two weeks during each condition
Average daily caloric intake (kcal/day)
Calculated from photographic diet diaries. Higher kcal indicates greater caloric intake.
Time frame: Measured for 3 days during each condition
Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interests. Data shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.
Access criteria: Access to study IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact clinicalresearchsupportcenter@ucdenver.edu.
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Jun 2030, 43 months after the start.
Of 715 non-industry interventional studies with no phase under Insulin Resistance, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 43 months is above that.
Counting every sponsor, half of 755 studies reached it within 21 months; a quarter within 9 and three quarters within 40.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →